Cancer growth and anti-cancer treatments stimulate several adaptations in patients, including systemic inflammation and metabolic stress in several organs, resulting in impaired tissue function, reduced tolerance to chemotherapy, poor immune response and cachexia. The current oncology practice is focused on cancerdirected therapeutics, frequently disregarding the host status, missing the opportunity to consider and treat the cancer and the associated host alterations as a unique cancer disease.